{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:19:32Z","timestamp":1784647172230,"version":"3.55.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study evaluated the treatment outcomes of agomelatine on anhedonic state, anxiety\/somatic symptoms, and sexual function in Chinese patients with major depressive disorder (MDD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In total, 93 adult patients with MDD were enrolled, and 68 of them were included in a prospective, open-label, multicenter clinical study. All patients received agomelatine monotherapy during a 9-week treatment phase. The effectiveness of the treatment was reflected by the improvement of anhedonia and somatic symptoms based on the 17-item Hamilton Depression Rating Scale (HAMD-17). In addition, the Arizona Sexual Dysfunction Scale (ASEX), Sheehan Disability Scale (SDS), and Short Form of Quality-of-Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) were administered to all participants at baseline and at the 3-, 6-, and 9-week follow-ups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 9 weeks of treatment with agomelatine, the response and remission rates were 73.5% and 39.7%, respectively. Somatic symptoms significantly improved at week 9 (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), and significant effects were also observed on the HAMD anhedonia items (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). The patients exhibited lower levels of disease severity (the SDS score dropped from 15.52 \u00b1 4.7 to 7.09 \u00b1 5.62 at week 9; the ASEX score dropped from 21.89 \u00b1 4.06 to 16.19 \u00b1 4.79, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and higher levels of QOL (the Q-LES-Q-SF score dropped from 41.02 \u00b1 5.99 to 50.49 \u00b1 8.57, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) during the follow-up. Furthermore, treatment with agomelatine improved depressive symptoms without causing serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These analyses indicate that agomelatine is a treatment option for improving anhedonic status, anxiety\/somatic symptoms, and sexual dysfunction in MDD patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1115008","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:19:25Z","timestamp":1682029165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder"],"prefix":"10.3389","volume":"14","author":[{"given":"Juan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Meng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Bing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1037\/abn0000023","article-title":"Self-referential processing in depressed adolescents: a high-density event-related potential study","volume":"124","author":"Auerbach","year":"2015","journal-title":"J Abnorm Psychol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jama.285.5.535","article-title":"Burden of disease: implications for future research","volume":"285","author":"Michaud","year":"2001","journal-title":"JAMA."},{"key":"B3","unstructured":"GenevaWorld Health OrganizationDepression2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1747-5341-3-14","article-title":"Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?","volume":"3","author":"Ioannidis","year":"2008","journal-title":"Philos Ethics Humanit Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/01.psy.0000204851.15499.fc","article-title":"Comorbid depression, chronic pain, and disability in primary care","volume":"68","author":"Arnow","year":"2006","journal-title":"Psychosom Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1017\/S0033291713002900","article-title":"Depression is more than the sum score of its parts: individual DSM symptoms have different risk factors","volume":"44","author":"Fried","year":"2014","journal-title":"Psychol Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1480","DOI":"10.4088\/JCP.13097TX1C","article-title":"Residual symptoms in depression: prevalence and impact","volume":"76","author":"Nierenberg","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajp.2017.02.013","article-title":"Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample","volume":"27","author":"Gao","year":"2017","journal-title":"Asian J Psychiatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1034\/j.1600-0447.2001.103002122.x","article-title":"Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands mental health survey and incidence study (NEMESIS)","volume":"103","author":"Spijker","year":"2001","journal-title":"Acta Psych Scand."},{"key":"B11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neubiorev.2010.06.006","article-title":"Reconsidering anhedonia in depression: Lessons from translational neuroscience","volume":"35","author":"Treadway","year":"2011","journal-title":"Neurosci Biobehav Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.biopsych.2009.11.001","article-title":"Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment","volume":"67","author":"McCabe","year":"2010","journal-title":"Biol Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1192\/bjp.bp.108.051110","article-title":"Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study","volume":"195","author":"Price","year":"2009","journal-title":"Br J Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1176\/appi.ps.52.11.1469","article-title":"Can recovery from depression be achieved?","volume":"52","author":"Shelton","year":"2001","journal-title":"Psych Serv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4103\/2319-4170.106138","article-title":"Correlations between sexual dysfunction, depression, anxiety, and somatic symptoms among patients with major depressive disorder","volume":"35","author":"Lin","year":"2012","journal-title":"Chang Gung Med J."},{"key":"B16","first-page":"10","article-title":"Somatic symptoms in depression and antidepressants","volume":"44","author":"Mathew","year":"1983","journal-title":"J Clin Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4088\/JCP.v66n1110","article-title":"Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine","volume":"66","author":"Nelson","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.euroneuro.2018.05.006","article-title":"12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25\u201350 mg\/day) vs. escitalopram (10\u201320 mg\/day) in out-patients with severe generalized anxiety disorder","volume":"28","author":"Stein","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jad.2013.01.020","article-title":"Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?","volume":"149","author":"Novick","year":"2013","journal-title":"J Affect Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1037\/0021-843X.117.2.300","article-title":"The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America?","volume":"117","author":"Ryder","year":"2008","journal-title":"J Abnorm Psychol."},{"key":"B21","first-page":"91","article-title":"Therapeutic adherence in primary care depressed patients: a longitudinal study","volume":"42","author":"Serrano","year":"2014","journal-title":"Actas Esp Psiquiatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4088\/JCP.v62n07a04","article-title":"Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder","volume":"62","author":"Silverstone","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.36740\/WLek201910125","article-title":"Sexual problems in the patients with psychiatric disorders","volume":"72","author":"Piontek","year":"2019","journal-title":"Wiad Lek."},{"key":"B24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-079X.1998.tb00556.x","article-title":"Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat","volume":"25","author":"Masson-P\u00e9vet","year":"1998","journal-title":"J Pineal Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.103.051797","article-title":"The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways","volume":"306","author":"Millan","year":"2003","journal-title":"J Pharmacol Exp Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40261-020-00957-9","article-title":"Agomelatine in standard medical practice in depressed patients: results of a 1-year multicentre observational study in France","volume":"40","author":"Gorwood","year":"2020","journal-title":"Clin Drug Investig."},{"key":"B27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40263-015-0267-6","article-title":"Network meta-analysis and cost-effectiveness analysis of new generation antidepressants","volume":"29","author":"Khoo","year":"2015","journal-title":"CNS Drugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1017\/S1461145711001301","article-title":"Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal","volume":"15","author":"Singh","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","article-title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study","volume":"19","author":"Montgomery","year":"2004","journal-title":"Int Clin Psychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2174\/1874467214666211209142546","article-title":"Agomelatine: an astounding sui-generis antidepressant?","volume":"15","author":"Naveed","year":"2022","journal-title":"Curr Mol Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0000000000000878","article-title":"Efficacy and safety of agomelatine vs. paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, non-inferiority, randomized controlled trial","volume":"38","author":"Yu","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"B34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1192\/bjp.152.5.660","article-title":"Validity and reliability of the Chinese Hamilton Depression Rating Scale","volume":"152","author":"Zheng","year":"1988","journal-title":"Br J Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00004850-200503000-00004","article-title":"The relationship between early changes in the HAMD-17 anxiety\/somatization factor items and treatment outcome among depressed outpatients","volume":"20","author":"Farabaugh","year":"2005","journal-title":"Int Clin Psychopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/da.20467","article-title":"Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?","volume":"25","author":"Dombrovski","year":"2008","journal-title":"Depress Anxiety."},{"key":"B37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.bbi.2021.03.022","article-title":"Inflammatory cytokines, complement factor H and anhedonia in drug-na\u00efve major depressive disorder","volume":"95","author":"Tang","year":"2021","journal-title":"Brain Behav Immun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The arizona sexual experience scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J Sex Marital Therapy."},{"key":"B39","first-page":"322","article-title":"The influence of antipsychotic treatment on sexual function in remitted male schizophrenic patients and the correlation with plasma prolactin concentrations (in Chinese)","volume":"20","author":"Zhu","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/appy.12182","article-title":"Validity and reliability of the Chinese version of the Sheehan disability scale (SDS-C)","volume":"7","author":"Leu","year":"2015","journal-title":"Asia Pac Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jad.2008.06.019","article-title":"Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep","volume":"111","author":"Endicott","year":"2008","journal-title":"J Affect Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s11136-013-0528-0","article-title":"Validity and reliability of the Chinese version of the short form of quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-SF)","volume":"23","author":"Lee","year":"2014","journal-title":"Qual Life Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/hup.2557","article-title":"Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study","volume":"31","author":"Gargoloff","year":"2016","journal-title":"Hum Psychopharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S703","DOI":"10.1016\/j.euroneuro.2011.07.004","article-title":"Agomelatine: a narrative review","volume":"21","author":"Demyttenaere","year":"2011","journal-title":"Eur Neuropsychopharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/YIC.0b013e32833a86aa","article-title":"Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: a randomized, double-blind study","volume":"25","author":"Hale","year":"2010","journal-title":"Int Clin Psychopharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.npp.1300433","article-title":"Effects of chronic fluoxetine in animal models of anxiety and depression","volume":"29","author":"Dulawa","year":"2004","journal-title":"Neuropsychopharmacology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/026988110201600304","article-title":"Fluoxetine treatment of depressed patients with comorbid anxiety disorders","volume":"16","author":"Sonawalla","year":"2002","journal-title":"J Psychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/da.21951","article-title":"Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review","volume":"29","author":"Thaler","year":"2012","journal-title":"Depress Anxiety."},{"key":"B50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/appi.neuropsych.11090216","article-title":"Agomelatine in depressive disorders: its novel mechanisms of action","volume":"24","author":"Srinivasan","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/npp.2009.72","article-title":"Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus","volume":"34","author":"Soumier","year":"2009","journal-title":"Neuropsychopharmacology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/FBP.0b013e3282de7929","article-title":"The role of hippocampus in anxiety: intracerebral infusion studies","volume":"18","author":"Engin","year":"2007","journal-title":"Behav Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuron.2009.11.031","article-title":"Are the dorsal and ventral hippocampus functionally distinct structures?","volume":"65","author":"Fanselow","year":"2010","journal-title":"Neuron."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/brain\/awz167","article-title":"Impaired reward-related learning signals in remitted unmedicated patients with recurrent depression","volume":"142","author":"Geugies","year":"2019","journal-title":"Brain."},{"key":"B55","doi-asserted-by":"publisher","first-page":"103507","DOI":"10.1016\/j.brat.2019.103507","article-title":"Distress and anhedonia as predictors of depression treatment outcome: a secondary analysis of a randomized clinical trial","volume":"125","author":"Khazanov","year":"2020","journal-title":"Behav Res Ther."},{"key":"B56","first-page":"109","article-title":"Major depressive disorder, anhedonia and agomelatine: an open-label study","volume":"25","author":"Di Giannantonio","year":"2011","journal-title":"J Biol Regul Homeost Agents."},{"key":"B57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/JCP.0b013e31825d6c25","article-title":"Agomelatine vs. venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study","volume":"32","author":"Martinotti","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14656566.2019.1574747","article-title":"Agomelatine for depression: expanding the horizons?","volume":"20","author":"Norman","year":"2019","journal-title":"Exp Opin Pharmacother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00004850-200209000-00004","article-title":"Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study","volume":"17","author":"L\u00f4o","year":"2002","journal-title":"Int Clin Psychopharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/JCP.0b013e318172b48c","article-title":"A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR","volume":"28","author":"Kennedy","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/hup.1243","article-title":"The effects of agomelatine on sexual function in depressed patients and healthy volunteers","volume":"26","author":"Montejo","year":"2011","journal-title":"Hum Psychopharmacol."},{"key":"B62","first-page":"10","article-title":"Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1,022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction","volume":"62","author":"Montejo","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/0269881108096507","article-title":"Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale","volume":"24","author":"Montejo","year":"2010","journal-title":"J Psychopharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/0004867414525837","article-title":"Comparison of agomelatine and selective serotonin reuptake inhibitors\/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials","volume":"48","author":"Huang","year":"2014","journal-title":"Aust N Z J Psychiatry."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/sleep\/zsaa092","article-title":"Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses","volume":"43","author":"Mi","year":"2020","journal-title":"Sleep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00213-019-05385-y","article-title":"Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT(1) receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light","volume":"237","author":"Tchekalarova","year":"2020","journal-title":"Psychopharmacology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/11534420-000000000-00000","article-title":"Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness","volume":"24","author":"Kennedy","year":"2010","journal-title":"CNS Drugs."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1115008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:19:32Z","timestamp":1682029172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1115008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":67,"alternative-id":["10.3389\/fpsyt.2023.1115008"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1115008","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"article-number":"1115008"}}